Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA

Immunological Reviews

Volumn 250, Issue 1, 2012, Pages 180-198

  Julien, Jean Philippe ^a   Lee, Peter S ^a   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Env; Hemagglutinin antibody; HIV 1; Influenza; Structure

Indexed keywords

EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ ANTIBODY; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN ANTIBODY;

ALPHA HELIX; AMINO ACID SEQUENCE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY STRUCTURE; ANTIGEN RECOGNITION; ANTIGEN STRUCTURE; ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DRUG DESIGN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS; MEMBRANE FUSION; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; STRUCTURE ANALYSIS; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIGENIC VARIATION; GENE PRODUCTS, ENV; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HIV ANTIBODIES; HIV-1; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; MODELS, MOLECULAR; RECEPTORS, VIRUS; SPECIES SPECIFICITY; STRUCTURAL HOMOLOGY, PROTEIN; VIRUS INTERNALIZATION;

EID: 84867427047     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12005     Document Type: Article

References (199)

1. Gray RH, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-1153.
2. Forsman A, Weiss RA. Why is HIV a pathogen? Trends Microbiol 2008;16:555-560.
3. Gelderblom HR, Hausmann EH, Ozel M, Pauli G, Koch MA. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 1987;156:171-176.
4. Zhu P, et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci USA 2003;100:15812-15817.
5. Zhu P, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006;441:847-852.
6. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
7. Zhu P, Winkler H, Chertova E, Taylor KA, Roux KH. Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs. PLoS Pathog 2008;4:e1000203.
8. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008;455:109-113.
9. White TA, et al. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 2010;6:e1001249.
10. Wu SR, et al. Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Proc Natl Acad Sci USA 2010;107:18844-18849.
11. White TA, et al. Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. J Virol 2011;85:12114-12123.
12. Harris A, et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci USA 2011;108:11440-11445.
13. Moscoso CG, et al. Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding. Proc Natl Acad Sci USA 2011;108:6091-6096.
14. Hu G, Liu J, Taylor KA, Roux KH. Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J Virol 2011;85:2741-2750.
15. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-659.
16. Kwon YD, et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci USA 2012;109:5663-5668.
17. McLellan JS, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011;480:336-343.
18. Tran EE, et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 2012;8:e1002797.
19. Gallo SA, et al. The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003;1614:36-50.
20. Markovic I, Clouse KA. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res 2004;2:223-234.
21. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387:426-430.
22. Kilby JM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-1307.
23. Shu W, Liu J, Ji H, Radigen L, Jiang S, Lu M. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 2000;39:1634-1642.
24. Sia SK, Carr PA, Cochran AG, Malashkevich VN, Kim PS. Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci USA 2002;99:14664-14669.
25. Munoz-Barroso I, Salzwedel K, Hunter E, Blumenthal R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol 1999;73:6089-6092.
26. Kuhmann SE, Platt EJ, Kozak SL, Kabat D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 2000;74:7005-7015.
27. Pierson TC, Doms RW. HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 2003;281:1-27.
28. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 2005;79:12132-12147.
29. Klasse PJ. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 2007;369:245-262.
30. Magnus C, Rusert P, Bonhoeffer S, Trkola A, Regoes RR. Estimating the stoichiometry of human immunodeficiency virus entry. J Virol 2009;83:1523-1531.
31. Magnus C, Regoes RR. Analysis of the subunit stoichiometries in viral entry. PLoS ONE 2012;7:e33441.
32. Wilson IA, Skehel JJ, Wiley DC. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 1981;289:366-373.
33. Harris A, et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci USA 2006;103:19123-19127.
34. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000;69:531-569.
35. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988;333:426-431.
36. Sauter NK, et al. Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. Biochemistry 1989;28:8388-8396.
37. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994;371:37-43.
38. Air GM. Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. Proc Natl Acad Sci USA 1981;78:7639-7643.
39. Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, Nakajima K. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 1991;182:475-485.
40. Salzberg S. The contents of the syringe. Nature 2008;454:160-161.
41. Centers for Disease Control and Prevention (CDC). Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine-Marshfield, Wisconsin, 2007-08 influenza season. MMWR Morb Mortal Wkly Rep 2008;57:393-398.
42. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol 1986;59:377-383.
43. Korber B, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000;288:1789-1796.
44. Gaschen B, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-2360.
45. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008;6:143-155.
46. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001;58:19-42.
47. Back NK, et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994;199:431-438.
48. Kolchinsky P, Kiprilov E, Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001;75:2041-2050.
49. McCaffrey RA, Saunders C, Hensel M, Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 2004;78:3279-3295.
50. Kang SM, et al. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology 2005;331:20-32.
51. Li Y, et al. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 2008;82:638-651.
52. Wang CC, et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci USA 2009;106:18137-18142.
53. Binley JM, et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 2010;84:5637-5655.
54. Wanzeck K, Boyd KL, McCullers JA. Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice. Am J Respir Crit Care Med 2011;183:767-773.
55. Geyer H, Holschbach C, Hunsmann G, Schneider J. Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem 1988;263:11760-11767.
56. Hansen JE, Clausen H, Hu SL, Nielsen JO, Olofsson S. An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus. Arch Virol 1992;126:11-20.
57. Bernstein HB, Tucker SP, Hunter E, Schutzbach JS, Compans RW. Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol 1994;68:463-468.
58. Doores KJ, et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci USA 2010;107:13800-13805.
59. Igarashi M, Ito K, Kida H, Takada A. Genetically destined potentials for N-linked glycosylation of influenza virus hemagglutinin. Virology 2008;376:323-329.
60. Das SR, Puigbo P, Hensley SE, Hurt DE, Bennink JR, Yewdell JW. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog 2010;6:e1001211.
61. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981;289:373-378.
62. Wilson IA, Ladner RC, Skehel JJ, Wiley DC. The structure and role of the carbohydrate moieties of influenza virus haemagglutinin. Biochem Soc Trans 1983;11:145-147.
63. Wei CJ, et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2010;2:24ra21.
64. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Jr., Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010;328:357-360.
65. Go EP, et al. Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J Proteome Res 2009;8:4231-4242.
66. Go EP, et al. Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 2011;85:8270-8284.
67. Bonomelli C, et al. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE 2011;6:e23521.
68. Wyatt R, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-711.
69. Johnson WE, Desrosiers RC. Viral persistance: HIV's strategies of immune system evasion. Annu Rev Med 2002;53:499-518.
70. Labrijn AF, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003;77:10557-10565.
71. Huang CC, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005;310:1025-1028.
72. Moore PL, et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006;80:2515-2528.
73. Sanchez-Martinez S, Lorizate M, Katinger H, Kunert R, Nieva JL. Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 2006;22:998-1006.
74. Moore PL, et al. The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2008;82:1860-1869.
75. Willey S, Aasa-Chapman MM. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol 2008;16:596-604.
76. Conley AJ, et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 1996;70:6751-6758.
77. Mascola JR. Defining the protective antibody response for HIV-1. Curr Mol Med 2003;3:209-216.
78. Hessell AJ, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009;15:951-954.
79. Hessell AJ, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009;5:e1000433.
80. Hessell AJ, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2009;84:1302-1313.
81. Doria-Rose NA, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009;83:188-199.
82. Sather DN, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009;83:757-769.
83. Simek MD, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009;83:7337-7348.
84. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009;15:866-870.
85. Barbas CF, 3rd, et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992;89:9339-9343.
86. Barbas CF, 3rd, et al. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 1993;230:812-823.
87. Buchacher A, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-369.
88. Calarese DA, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003;300:2065-2071.
89. Ofek G, et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004;78:10724-10737.
90. Cardoso RM, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005;22:163-173.
91. Zhou T, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007;445:732-737.
92. Julien JP, Bryson S, Nieva JL, Pai EF. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J Mol Biol 2008;384:377-392.
93. Walker LM, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-289.
94. Wu X, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011;333:1593-1602.
95. Scheid JF, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011;333:1633-1637.
96. Mouquet H, et al. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS ONE 2011;6:e24078.
97. Walker LM, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466-470.
98. Kwong PD, Mascola JR, Nabel GJ. Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1. Cell Host Microbe 2009;6:292-294.
99. Clapham PR, Lu S. Vaccinology: precisely tuned antibodies nab HIV. Nature 2011;477:416-417.
100. Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harb Perspect Med 2012;2:a007039.
101. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337:183-186.
102. Huse WD, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989;246:1275-1281.
103. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993;67:2552-2558.
104. Zhou T, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010;329:811-817.
105. Ryu SE, Hendrickson WA. Structure and design of broadly-neutralizing antibodies against HIV. Mol Cells 2012;doi:10.1007/s10059-012-0104-4.
106. Chen L, et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009;326:1123-1127.
107. Diskin R, et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011;334:1289-1293.
108. Nelson JD, et al. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 2007;81:4033-4043.
109. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008;72:54-84.
110. Gach JS, Leaman DP, Zwick MB. Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. Curr Top Med Chem 2011;11:2997-3021.
111. Bryson S, Julien JP, Hynes RC, Pai EF. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J Virol 2009;83:11862-11875.
112. Salzwedel K, West JT, Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol 1999;73:2469-2480.
113. Bellamy-McIntyre AK, et al. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem 2007;282:23104-23116.
114. Poumbourios P, el Ahmar W, McPhee DA, Kemp BE. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J Virol 1995;69:1209-1218.
115. Suarez T, Gallaher WR, Agirre A, Goni FM, Nieva JL. Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion. J Virol 2000;74:8038-8047.
116. Suarez T, Nir S, Goni FM, Saez-Cirion A, Nieva JL. The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: a novel fusogenic sequence. FEBS Lett 2000;477:145-149.
117. Saez-Cirion A, et al. Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J Biol Chem 2002;277:21776-21785.
118. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001;166:6257-6265.
119. Alfsen A, Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem 2002;277:25649-25659.
120. Yu H, Alfsen A, Tudor D, Bomsel M. The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent. Cell Calcium 2008;43:73-82.
121. Schibli DJ, Montelaro RC, Vogel HJ. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry 2001;40:9570-9578.
122. Sun ZY, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008;28:52-63.
123. Pejchal R, et al. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol 2009;83:8451-8462.
124. Song L, et al. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci USA 2009;106:9057-9062.
125. Kim M, et al. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol 2011;18:1235-1243.
126. Walker LM, et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc Natl Acad Sci USA 2011;108:20125-20129.
127. Lavine CL, Lao S, Montefiori DC, Haynes BF, Sodroski JG, Yang X. High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. J Virol 2012;86:2153-2164.
128. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373-10382.
129. Eggink D, et al. Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 2010;401:236-247.
130. Scanlan CN, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 2002;76:7306-7321.
131. Walker BD, et al. Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci USA 1987;84:8120-8124.
132. Geijtenbeek TB, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-597.
133. Bonsignori M, et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 2012;86:4688-4692.
134. Pejchal R, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011;334:1097-1103.
135. Walker LM, Bowley DR, Burton DR. Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library. J Mol Biol 2009;389:365-375.
136. Pejchal R, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA 2010;107:11483-11488.
137. Pancera M, et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 2010;84:8098-8110.
138. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982;31:417-427.
139. Whittle JR, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 2011;108:14216-14221.
140. Ekiert DC, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop into the receptor binding site. Nature, 2012;doi:10.1038/nature11414.
141. Liao HX, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods 2009;158:171-179.
142. Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol 2012;2:134-141.
143. Throsby M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008;3:e3942.
144. Kashyap AK, et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 2008;105:5986-5991.
145. Ekiert DC, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009;324:246-251.
146. Sui J, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009;16:265-273.
147. Corti D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010;120:1663-1673.
148. Wrammert J, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011;208:181-193.
149. Wei CJ, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010;329:1060-1064.
150. Ekiert DC, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011;333:843-850.
151. Corti D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011;333:850-856.
152. Dreyfus C, et al. Highly conserved protective epitopes on influenza B viruses. Science 2012;337:1343-1348.
153. Kwong PD, Wilson IA. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 2009;10:573-578.
154. Barbey-Martin C, et al. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology 2002;294:70-74.
155. Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP, Jr., Bjorkman PJ. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci USA 2009;106:7385-7390.
156. Mouquet H, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010;467:591-595.
157. Ward CW, Gleeson PA, Dopheide TA. Carbohydrate composition of the oligosaccharide units of the haemagglutinin from the Hong Kong influenza virus A/Memphis/102/72. Biochem J 1980;189:649-652.
158. Mir-Shekari SY, Ashford DA, Harvey DJ, Dwek RA, Schulze IT. The glycosylation of the influenza A virus hemagglutinin by mammalian cells. A site-specific study. J Biol Chem 1997;272:4027-4036.
159. Phogat S, Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des 2007;13:213-227.
160. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010;22:358-366.
161. Dey B, et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 2009;5:e1000445.
162. Bhattacharyya S, et al. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies. J Biol Chem 2010;285:27100-27110.
163. Azoitei ML, et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 2011;334:373-376.
164. Kumar R, Tuen M, Li H, Tse DB, Hioe CE. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine 2011;29:9064-9074.
165. Ahmed FK, Clark BE, Burton DR, Pantophlet R. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine 2012;30:922-930.
166. Depetris RS, et al. Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem 2012;287:24239-24254.
167. Ofek G, et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci USA 2010;107:17880-17887.
168. Stanfield RL, Julien JP, Pejchal R, Gach JS, Zwick MB, Wilson IA. Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope. J Mol Biol 2011;414:460-476.
169. Azoitei ML, et al. Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J Mol Biol 2012;415:175-192.
170. Alam SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009;106:20234-20239.
171. Ofek G, et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010;84:2955-2962.
172. Xu H, et al. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J Virol 2010;84:1076-1088.
173. Julien JP, et al. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol 2010;84:4136-4147.
174. Guenaga J, Wyatt RT. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS Pathog 2012;8:e1002806.
175. Luallen RJ, et al. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. J Virol 2008;82:6447-6457.
176. Astronomo RD, et al. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol 2008;82:6359-6368.
177. Dunlop DC, et al. Antigenic mimicry of the HIV envelope by AIDS-associated pathogens. AIDS 2008;22:2214-2217.
178. Luallen RJ, et al. A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. J Virol 2009;83:4861-4870.
179. Dunlop DC, et al. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology 2010;20:812-823.
180. Doores KJ, et al. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci USA 2010;107:17107-17112.
181. Huber M, et al. Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J Virol 2010;84:10700-10707.
182. Chen W, Streaker ED, Russ DE, Feng Y, Prabakaran P, Dimitrov DS. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem Biophys Res Commun 2012;417:1164-1169.
183. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423-433.
184. West AP, Jr., Diskin R, Nussenzweig MC, Bjorkman PJ. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci USA 2012;109:E2083-E2090.
185. Wang TT, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010;107:18979-18984.
186. Steel J, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010;1:e000018-10.
187. Pica N, et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci USA 2012;109:2573-2578.
188. Hai R, et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 2012;86:5774-5781.
189. Fleishman SJ, et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 2011;332:816-821.
190. Whitehead TA, et al. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol 2012;30:543-548.
191. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE, Jr.. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 2011;85:10905-10908.
192. Krause JC, et al. Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol 2011;187:3704-3711.
193. Krause JC, et al. Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol 2012;86:6334-6340.
194. Okada J, et al. Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003. Virology 2010;397:322-330.
195. Okada J, et al. Localization of epitopes recognized by monoclonal antibodies that neutralized the H3N2 influenza viruses in man. J Gen Virol 2011;92:326-335.
196. Ohshima N, Iba Y, Kubota-Koketsu R, Asano Y, Okuno Y, Kurosawa Y. Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J Virol 2011;85:11048-11057.
197. Yoshida R, et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 2009;5:e1000350.
198. Pettersen EF, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605-1612.
199. Sheriff S, Hendrickson WA, Smith JL. Structure of myohemerythrin in the azidomet state at 1.7/1.3 Å resolution. J Mol Biol 1987;197:273-296.